Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

References

• YinDMorrisCRBatesJHGermanRREffect of misclassified underlying cause of death on survival estimates of colon and rectal cancerJ Natl Cancer Inst2011103141130113321697545
   PubMedGoogle Scholar
• EdwardsBKWardEKohlerBAAnnual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future ratesCancer2010116354457319998273
   PubMed Web of Science ®Google Scholar
• VogelaarIvan BallegooijenMSchragDHow much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatmentCancer200610771624163316933324
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDFedewaSAColorectal cancer statisticsCA Cancer J Clin201767317719328248415
   PubMed Web of Science ®Google Scholar
• LeeMSMenterDGKopetzSRight versus left colon cancer biology: integrating the consensus molecular subtypesJ Natl Compr Canc Netw201715341141928275039
   PubMed Web of Science ®Google Scholar
• FakihMGMetastatic colorectal cancer: current state and future directionsJ Clin Oncol201533161809182425918280
   PubMed Web of Science ®Google Scholar
• Van CutsemECervantesAAdamRESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnn Oncol20162781386142227380959
   PubMed Web of Science ®Google Scholar
• RittDAAbreu-BlancoMTBinduLInhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory CircuitMolecular Cell20166487588727889448
   PubMed Web of Science ®Google Scholar
• ChowdhuryIThompsonWEThomasKProhibitins role in cellular survival through Ras-Raf-MEK-ERK pathwayJournal of Cellular Physiology2014229998100424347342
   PubMed Web of Science ®Google Scholar
• AnSYangYWardRLiuYGuoXXXuTRA-Raf: a new star of the family of raf kinasesCrit Rev Biochem Mol Biol201550652053126508523
   PubMed Web of Science ®Google Scholar
• NeuzilletCTijeras-RaballandAde MestierLMEK in cancer and cancer therapyPharmacol Ther2013141216017124121058
   PubMed Web of Science ®Google Scholar
• RoskoskiRJrA historical overview of protein kinases and their targeted small molecule inhibitorsPharmacol Res201510012326207888
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• MartinelliEMorgilloFTroianiTCiardielloFCancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEKCancer Treat Rev201753616928073102
   PubMed Web of Science ®Google Scholar
• YaegerRCercekAO’ReillyEMPilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patientsClin Cancer Res20152161313132025589621
   PubMed Web of Science ®Google Scholar
• CavalieriSDi GuardoLCossaMCimminielloCDel VecchioMUnusual skin carcinomas induced by BRAF inhibitor for metastatic melanoma: a case reportJ Clin Diagn Res2017117Xd06Xd0828893027
   PubMedGoogle Scholar
• WarnePHVicianaPRDownwardJDirect interaction of Ras and the amino-terminal region of Raf-1 in vitroNature199336464353523558332195
   PubMed Web of Science ®Google Scholar
• CutlerREJrStephensRMSaracinoMRMorrisonDKAutoregulation of the Raf-1 serine/threonine kinaseProc Natl Acad Sci U S A19989516921492199689060
   PubMed Web of Science ®Google Scholar
• VojtekABHollenbergSMCooperJAMammalian Ras interacts directly with the serine/threonine kinase RafCell19937412052148334704
   PubMed Web of Science ®Google Scholar
• KornevAPTaylorSSDynamics-driven allostery in protein kinasesTrends Biochem Sci2015401162864726481499
   PubMed Web of Science ®Google Scholar
• KarouliaZGavathiotisEPoulikakosPINew perspectives for targeting RAF kinase in human cancerNat Rev Cancer2017171167669128984291
   PubMed Web of Science ®Google Scholar
• LavoieHTherrienMRegulation of RAF protein kinases in ERK signallingNat Rev Mol Cell Biol201516528129825907612
   PubMed Web of Science ®Google Scholar
• PalmieriLRastelliGalphaC helix displacement as a general approach for allosteric modulation of protein kinasesDrug Discov Today2013187–840741423195331
   PubMed Web of Science ®Google Scholar
• GarnettMJRanaSPatersonHBarfordDMaraisRWild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerizationMol Cell200520696396916364920
   PubMed Web of Science ®Google Scholar
• YaoZTorresNMTaoABRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibitionCancer Cell201528337038326343582
   PubMed Web of Science ®Google Scholar
• LitoPPratilasCAJosephEWRelief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomasCancer Cell201222566868223153539
   PubMed Web of Science ®Google Scholar
• PoulikakosPIZhangCBollagGShokatKMRosenNRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature2010464728742743020179705
   PubMed Web of Science ®Google Scholar
• HongAMoriceauGSunLExploiting drug addiction mechanisms to select against MAPKi-resistant melanomaCancer Discov201881749328923912
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med2012367181694170323020132
   PubMed Web of Science ®Google Scholar
• LiuMYangXLiuJEfficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trialsOncotarget2017819322583226928416755
   PubMedGoogle Scholar
• GonsalvesWIMahoneyMRSargentDJPatient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147J Natl Cancer Inst20141067dju10624925349
   PubMedGoogle Scholar
• OginoSBrahmandamMCantorMDistinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous componentMod Pathol2006191596816118624
   PubMed Web of Science ®Google Scholar
• ClancyCBurkeJPKaladyMFCoffeyJCBRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysisColorectal Dis20131512e711e71824112392
   PubMed Web of Science ®Google Scholar
• PopoviciVBudinskaETejparSIdentification of a poor-prognosis BRAF-mutant-like population of patients with colon cancerJ Clin Oncol201230121288129522393095
   PubMed Web of Science ®Google Scholar
• SamowitzWSSweeneyCHerrickJPoor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancersCancer Res200565146063606916024606
   PubMed Web of Science ®Google Scholar
• LochheadPKuchibaAImamuraYMicrosatellite instability and BRAF mutation testing in colorectal cancer prognosticationJ Natl Cancer Inst2013105151151115623878352
   PubMedGoogle Scholar
• SinicropeFAMahoneyMRSmyrkTCPrognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapyJ Clin Oncol201331293664367224019539
   PubMed Web of Science ®Google Scholar
• Sanz-GarciaEArgilesGElezETaberneroJBRAF mutant colorectal cancer: prognosis, treatment and new perspectivesAnn Oncol201728112648265729045527
   PubMed Web of Science ®Google Scholar
• Hall-JacksonCAEyersPACohenPParadoxical activation of Raf by a novel Raf inhibitorChem Biol19996855956810421767
   PubMed Web of Science ®Google Scholar
• TaberneroJGarcia-CarboneroRCassidyJSorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trialClin Cancer Res20131992541255023532888
   PubMed Web of Science ®Google Scholar
• SamalinEBoucheOThezenasSSorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre phase I/II trialBr J Cancer201411051148115424407191
   PubMed Web of Science ®Google Scholar
• DoKCaoLKangZA phase II study of sorafenib combined with cetuximab in EGFR-expressing, KRAS-mutated metastatic colorectal cancerClin Colorectal Cancer201514315416125861837
   PubMed Web of Science ®Google Scholar
• TakleAKBrownMJDaviesSThe identification of potent and selective imidazole-based inhibitors of B-Raf kinaseBioorg Med Chem Lett200616237838116260133
   PubMed Web of Science ®Google Scholar
• HoeflichKPHerterSTienJAntitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppressionCancer Res20096973042305119276360
   PubMed Web of Science ®Google Scholar
• JohnsonKLiuLMajdzadehNInhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugsJ Neurochem200593353854815836613
   PubMed Web of Science ®Google Scholar
• SheltonJGMoyePWSteelmanLSDifferential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferationLeukemia20031791765178212970777
   PubMed Web of Science ®Google Scholar
• TsaiJLeeJTWangWDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProc Natl Acad Sci U S A200810583041304618287029
   PubMed Web of Science ®Google Scholar
• BollagGHirthPTsaiJClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature2010467731559659920823850
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• FalchookGSLongGVKurzrockRDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialLancet201237998291893190122608338
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• KopetzSDesaiJChanEPhase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancerJ Clin Oncol201533344032403826460303
   PubMed Web of Science ®Google Scholar
• HymanDMPuzanovISubbiahVVemurafenib in multiple nonmelanoma cancers with BRAF V600 mutationsN Engl J Med2015373872673626287849
   PubMed Web of Science ®Google Scholar
• CorcoranRBAtreyaCEFalchookGSCombined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancerJ Clin Oncol201533344023403126392102
   PubMed Web of Science ®Google Scholar
• HuangTKarsyMZhugeJZhongMLiuDB-Raf and the inhibitors: from bench to bedsideJ Hematol Oncol201363023617957
   PubMed Web of Science ®Google Scholar
• van GeelRTaberneroJElezEA phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancerCancer Discov20177661061928363909
   PubMed Web of Science ®Google Scholar
• ZhangCSpevakWZhangYRAF inhibitors that evade paradoxical MAPK pathway activationNature2015526757458358626466569
   PubMed Web of Science ®Google Scholar
• OkaniwaMHiroseMAritaTDiscovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivativesJ Med Chem201356166478649423906342
   PubMed Web of Science ®Google Scholar
• NakamuraAAritaTTsuchiyaSAntitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanomaCancer Res201373237043705524121489
   PubMed Web of Science ®Google Scholar
• SunYAlbertaJAPilarzCA brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomasNeuro Oncol201719677478528082416
   PubMed Web of Science ®Google Scholar
• VakanaEPrattSBlosserWLY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancerOncotarget2017869251926627999210
   PubMedGoogle Scholar
• ChenSHZhangYVan HornRDOncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120Cancer Discov20166330031526732095
   PubMed Web of Science ®Google Scholar
• YaoYMDonohoGPIversenPWMouse PDX trial suggests synergy of concurrent inhibition of RAF and EGFR in colorectal cancer with BRAF or KRAS mutationsClin Cancer Res201723185547556028611205
   PubMed Web of Science ®Google Scholar
• SaturnoGLopesFGirottiMRTherapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer modelsEur J Cancer201661S199
   Web of Science ®Google Scholar
• GirottiMRLopesFPreeceNParadox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaCancer Cell2015271859625500121
   PubMed Web of Science ®Google Scholar
• NishiguchiGARicoATannerHDesign and discovery of N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-y l)-3-(trifluoromethyl)benzamide (RAF709): a potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancersJ Med Chem201760124869488128557458
   PubMed Web of Science ®Google Scholar
• HongSPAhnSKDiscovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancerLife Sci2017183374428645859
   PubMed Web of Science ®Google Scholar
• TutukaCSAAndrewsMCMariadasonJMPLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adeno-carcinoma cells and prevents paradoxical MAPK pathway activationMol Cancer201716111228659148
   PubMedGoogle Scholar
• HartsoughEJKugelCHVidoMJResponse and resistance to paradox breaking BRAF inhibitor in melanomas in vivo and ex vivoMol Cancer Ther2018171849529133617
   PubMed Web of Science ®Google Scholar
• WaizeneggerICBaumASteurerSA novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferationMol Cancer Ther201615335436526916115
   PubMed Web of Science ®Google Scholar
• JamesJRuggeriBArmstrongRCCEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activityMol Cancer Ther201211493094122319199
   PubMed Web of Science ®Google Scholar
• CorcoranRBAndreTAtreyaCECombined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal CancerCancer Discovery2018842844329431699
   PubMed Web of Science ®Google Scholar
• SundarRHongDSKopetzSYapTATargeting BRAF-mutant colorectal cancer: progress in combination strategiesCancer Discov20177655856028576843
   PubMed Web of Science ®Google Scholar
• AtreyaCEVan CutsemEBendellJCUpdated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)J Clin Oncol20153315_suppl103
   Web of Science ®Google Scholar
• TaberneroJGeelRVGurenTKPhase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)J Clin Oncol201634354427573652
   PubMed Web of Science ®Google Scholar
• CorcoranRBAndréTYoshinoTEfficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)Ann Oncol201627455O
   Web of Science ®Google Scholar
• MaoMTianFMariadasonJMResistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agentsClin Cancer Res201219365766723251002
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med2004351433734515269313
   PubMed Web of Science ®Google Scholar
• YangHHigginsBKolinskyKAntitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancerCancer Res201272377978922180495
   PubMed Web of Science ®Google Scholar
• HongDSMorrisVKEl OstaBPhase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutationCancer Discov20166121352136527729313
   PubMed Web of Science ®Google Scholar
• KopetzSMcDonoughSLLenzH-JRandomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)J Clin Oncol20173515_suppl3505
   Google Scholar
• ChenGGaoCGaoXWnt/beta-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancerMol Cancer Ther201817480681329167314
   PubMed Web of Science ®Google Scholar
• PekMYatimSChenYOncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancerOncogene201736354975498628459468
   PubMed Web of Science ®Google Scholar
• EmeryCMMonacoKAWangPBRAF-inhibitor associated MEK mutations increase RAF-dependent and -independent enzymatic activityMol Cancer Res201715101431144428655712
   PubMed Web of Science ®Google Scholar
• FreemanAKRittDAMorrisonDKEffects of Raf dimerization and its inhibition on normal and disease-associated Raf signalingMol Cell201349475175823352452
   PubMed Web of Science ®Google Scholar
• JonesJCRenfroLAAl-ShamsiHO(Non-V600) BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancerJ Clin Oncol201735232624263028486044
   PubMed Web of Science ®Google Scholar
• WanPTGarnettMJRoeSMMechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAFCell2004116685586715035987
   PubMed Web of Science ®Google Scholar
• SehdevACramerHMIbrahimAAYoungerAEO’NeilBHPathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literatureDiscov Med20162111734134727355330
   PubMed Web of Science ®Google Scholar
• PalmerACSorgerPKCombination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergyCell201717116781691.e1329245013
   PubMed Web of Science ®Google Scholar
• JonesJCRenfroLAAl-ShamsiHO(Non-V600) BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal CancerJournal of Clinical Oncology2017352624263028486044
   PubMed Web of Science ®Google Scholar
• WanPTGarnettMJRoeSMMechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAFCell200411685586715035987
   PubMed Web of Science ®Google Scholar
• SehdevACramerHMIbrahimAAPathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literatureDiscovery Medicine20162134134727355330
   PubMed Web of Science ®Google Scholar
• PalmerACSorgerPKCombination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or SynergyCell201717116781691.e161329245013
   PubMed Web of Science ®Google Scholar